the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Share this:
Brief Title Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
Official Title Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Principal Investigator Hahn, Olwen
Brief Summary To assess the effect of tucatinib vs. placebo in combination with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on independent central radiology review.
Gender All
Ages 18 Years
Enrollment 480
Accepts Healthy Volunteers No
Lead Sponsor Cascadian Therapeutics Inc.Industry
Collaborator
Study Design
Study Phase Phase 2
Study Type Interventional
Contact Name Erica Stringer-Reasor, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition HER2 Positive Breast Cancer
Detail for Health Professional (on clinicaltrials.gov)
More clinical trials by this PI